Duke University Medical Center, Durham, North Carolina, USA.
Address correspondence to: Claude A. Piantadosi, Duke University Medical Center, Box 3315, Duke South Hospital, Durham, North Carolina 27710, USA. Phone: 919.684.6143; E-mail: email@example.com.
First published November 14, 2016 - More info
See the related article beginning on page 4654.
Nitric oxide (NO) is a potent mediator of blood vessel dilation and is released by several cell sources. Red blood cells (rbc) release NO when hemoglobin that has been S-nitrosylated at Cys93 of the β-chain (βCys93) transitions from the oxygenated form to the deoxygenated form. This transition occurs in response to reduced tissue oxygenation and is an important physiologic regulator of hypoxic vasodilation. In this issue of the JCI, Zhang and colleagues demonstrate that S-nitrosylation of hemoglobin at βCys93 is important for tissue oxygenation after cardiac injury. Mice harboring mutations that prevent S-nitrosylation of βCys93 had higher rates of morbidity and mortality following cardiac injury compared with WT; however, adaptive cardiac vascularization was increased in some mutant mice and reduced cardiac injury in these animals. The results of this study reveal a previously unexplored role of S-nitrosylated hemoglobin in cardioprotection.
The red blood cell (rbc) dilates peripheral blood vessels during episodic local hypoxia, and this capacity is mediated by the release of low–molecular weight vasodilators, one of which conveys nitric oxide (NO) bioactivity to the blood vessel from S-nitrosohemoglobin (SNO-Hb). SNO-Hb releases NO activity allosterically when hemoglobin transitions from the R (oxygenated) to the T (deoxygenated) state, thereby improving local vasodilation during O2 transport to cells. SNO-Hb is found chiefly on the hemoglobin β-chain at the highly conserved βCys93 residue, and approximately 1 in every 1,000 β-chains carries a molecule of NO that is released as low–molecular weight SNO, for instance, on thiol compounds such as cysteinyl-NO (CSNO) or glutathionyl-NO (GSNO), to facilitate rbc-mediated vasodilation. A study by Zhang et al. in this issue reveals that the loss of βCys93 SNO-Hb results in highly detrimental consequences and impairs rbc blood-flow regulation in myocardial infarction (MI) and ventricular pressure overload in mice. Together, these results indicate that this rbc system has a compelling influence on the coronary circulation (1).
Physiologically, rbc-mediated vasodilation is a characteristic of native rbc, which are able to signal changes in oxygen tension (PO2) through graded vasodilator and vasoconstrictor activity that pairs the vasoactive responses of intact blood vessels with changes in tissue O2 availability. Thus, NO is carried by rbc in the circulation, together with O2 and CO2, as a respiratory gas. In this paradigm, SNO-Hb supports tissue oxygenation during periods of high O2 demand or during hypoxemia or ischemia by facilitating the microvascular delivery and distribution of O2 to respiring cells (2).
Despite strong proof-of-principle that SNO-Hb is important for tissue oxygenation under physiological conditions, the effect of SNO-Hb dysfunction in disease models is not well understood, even though low SNO-Hb levels have been implicated in the vascular problems of diabetes, sickle cell anemia, congestive heart failure, pulmonary hypertension, and preeclampsia and in the adverse effects of blood transfusions (2). Detection of the physiological effects specific to SNO-Hb is complicated by the fact that endothelial NO synthase (NOS3) also participates in blood flow regulation and that endothelial dysfunction interferes with NO-dependent vasodilation. Moreover, rbc SNO-Hb derives in part from NOS3 (3), which up to now, has made it difficult for specific NO species to be assigned as the cause for defects in tissue blood flow regulation.
Any definitive test to detect SNO-Hb–specific contributions requires a physiologically accurate mouse model, in which murine Hb is replaced with human Hb. The generation of such mice was technically challenging because the human Hb has only one β-chain while the mouse Hb has two β-chains (major and minor). A humanized βCys93-null Hb mouse containing a βCys93Ala substitution was constructed at the University of Alabama at Birmingham by Townes and reported by Isbell et al. in 2008 (4). In characterizing these mice, Isbell et al. specified that they could detect no role for βCys93 in hypoxic vasodilation; however, their measurements (O2-binding curves, cardiac output, blood pressure, and exercise tolerance) lacked the resolution needed to detect the SNO-Hb–specific microcirculatory physiology of tissue O2 transfer during hypoxia.
In 2015, Zhang and colleagues of the Stamler laboratory at Case Western Reserve finally detected defects in blood flow and tissue oxygenation in the mice lacking βCys93 (5). In that work, mice lacking the βC93 SNO-binding site (some mice also contained ~10% human fetal α2γ2 tetramers to improve fetal survivability) were found by analyzing Hb-bound NO and shown to have absolute SNO-Hb levels that were similar to those of WT mice; however, hypoxic unloading of the rbc SNO pool in the absence of βCys93 was far less than in WT mice and lacked clear allosteric SNO-Hb kinetics. Additionally, animals lacking βCys93 displayed significantly increased fetal mortality, and live animals subsequently developed myocardial ischemia and cardiovascular decompensation and displayed greater mortality during short-term hypoxia, thus supporting the modern view of a three-gas respiratory cycle.
The fundamental findings of the Stamler group in 2015, which demonstrated that mice with the βCys93A mutation had increased MI and cardiogenic shock under hypoxia, also implied that rbc operating through allosterically coupled SNO-Hb activity play an important protective role in the heart that could have a meaningful impact on ischemic or hypertensive heart disease and heart failure. The Stamler group now reports, in mouse models of heart disease, lack of SNO at βCys93 enhances cardiac injury and overall mortality after left coronary artery occlusion–induced MI and following pressure overload–induced cardiac hypertrophy in the transverse aortic constriction (TAC) model (1). Interestingly, some of the βCys93-mutant mice exhibited the capacity to increase cardiac vascular collaterals via an unknown mechanism, and mice with this adaptation developed less ischemic injury after MI and had a better outcome. For instance, in the absence of collateralization, 18% of γβC93 control mice died after MI, but in the βC93A (and γβC93A) strains, more than 50% of the mice died. The TAC model produced similarly higher mortality rates in the βC93A strains; however, mutant mice that survived longer than five days after TAC showed reduced ejection fractions, fractional shortening, and cardiac output as well as increased dilation of the left ventricle compared with WT mice after four weeks.
The finding by Zhang et al. that the presence of Hb βC93 mitigates both ischemic and pressure overload–induced heart damage demonstrates the importance of rbc-derived SNO-based vasodilation in cardiac protection. By implication, rbc SNO-Hb levels might prove to be a useful biomarker of human cardiac disease or cardiovascular risk. Additionally, manipulation of SNO-Hb may have potential as a therapeutic target to improve tissue oxygenation in cardiovascular states of compromise.
This work was supported by two grants from the NIH: R01-AI095424 and P01 HL108801 (to C. Piantodosi).
Conflict of interest: The author has declared that no conflict of interest exists.
Reference information: J Clin Invest. 2016;126(12):4402–4403. doi:10.1172/JCI91303.
See the related article beginning on page 4654.